Our data would suggest that application of putative PHLPP2 agonists or liver-specific delivery of non-specific PHLPP activators52 have the potential to stem the tide of obesity-induced NAFLD. This evidence concerns the gene PHLPP2 and metabolic dysfunction-associated steatotic liver disease.